Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a strong sell rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

Several other research firms have also commented on MIST. Cantor Fitzgerald initiated coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, October 12th. Finally, HC Wainwright reissued a “buy” rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.40.

Milestone Pharmaceuticals Trading Down 20.6%

NASDAQ:MIST traded down $0.14 on Friday, hitting $0.52. 4,142,608 shares of the stock were exchanged, compared to its average volume of 1,227,676. The stock has a market cap of $64.74 million, a PE ratio of -0.75 and a beta of 1.07. The company has a current ratio of 8.13, a quick ratio of 7.92 and a debt-to-equity ratio of 3.25. The stock has a fifty day moving average of $0.80 and a 200-day moving average of $1.31. Milestone Pharmaceuticals has a fifty-two week low of $0.50 and a fifty-two week high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The firm had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $1.00 million. As a group, equities analysts expect that Milestone Pharmaceuticals will post -0.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MIST. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth approximately $68,000. Valeo Financial Advisors LLC increased its stake in shares of Milestone Pharmaceuticals by 12.2% in the third quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock worth $127,000 after buying an additional 16,000 shares during the last quarter. RVW Wealth LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter valued at $994,000. HighTower Advisors LLC raised its holdings in Milestone Pharmaceuticals by 100.0% in the second quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock valued at $27,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC raised its holdings in Milestone Pharmaceuticals by 21.1% in the second quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock valued at $455,000 after acquiring an additional 59,200 shares in the last quarter. 86.18% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Milestone Pharmaceuticals

Investors following MIST have been watching these stories:

• Positive Sentiment: CARDAMYST product revenue reached about $1.0 million, up 73% from the prior quarter, with roughly 3,400 prescriptions and coverage across about two-thirds of commercially insured lives. CARDAMYST and runway update
• Positive Sentiment: The company plans to cut operating expenses by about 30%, while keeping its sales team and AFib-RVR Phase 3 program in place. It expects $145.4 million in cash and investments to fund operations into late 2028, beyond the trial’s anticipated second-half 2028 data readout. Company results and cost-efficiency measures
• Negative Sentiment: The CFO and CMO have left the leadership team. Although cost reductions should conserve cash, the departures and the need to scale back spending may raise concerns about execution and commercialization. Cost-cutting and leadership update

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.